Related Experiment Videos
Experience with cyclosporine in endogenous uveitis posterior
D A Hesselink1, G S Baarsma, R W A M Kuijpers
1Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Rotterdam, The Netherlands. d.a.hesselink@erasmusmc.nl
Transplantation Proceedings
|March 26, 2004
Summary
Cyclosporine (CsA) improves vision in endogenous posterior uveitis (EPU) but causes side effects. New treatments are being evaluated to reduce EPU morbidity and therapy-related adverse effects.
Area of Science:
- Ophthalmology
- Immunology
- Nephrology
Background:
- Endogenous posterior uveitis (EPU) is a serious ocular condition impacting vision.
- Cyclosporine (CsA) is a key immunosuppressant for EPU, offering improved visual outcomes.
- CsA treatment is associated with significant side effects, including nephrotoxicity and hypertension.
Purpose of the Study:
- To review the efficacy and limitations of cyclosporine (CsA) in treating endogenous posterior uveitis (EPU).
- To explore emerging therapeutic strategies for EPU aimed at reducing treatment-related morbidity and adverse effects.
Main Methods:
- Literature review of current and investigational therapies for EPU.
- Analysis of the benefits and drawbacks of cyclosporine (CsA) and alternative immunosuppressants.
Main Results:
- Cyclosporine (CsA) demonstrates effectiveness in improving visual prognosis for EPU patients.
- Nephrotoxicity and hypertension remain significant challenges with CsA therapy, even at low doses.
- Novel approaches like anti-TNF-alpha therapy and other immunosuppressants show promise.
Conclusions:
- While CsA is beneficial for EPU, its adverse effects necessitate alternative or complementary treatments.
- Future strategies focus on enhancing EPU management while minimizing toxicity and improving patient quality of life.